James B. Tananbaum, Director, 10% Owner at Latigo Biotherapeutics, Inc. (LTGO), bought 140,000 shares at $18.00 ($2.5M) on 2026-08-10, disclosed to the SEC on 2026-08-10.
Director James B. Tananbaum purchased $2.52M of LTGO at $18.00, marking the largest insider purchase in the company's history, signaling confidence in the non-opioid pain candidate's commercial potential. This high-value bet comes just days after the company completed its IPO and published clinical data in the New England Journal of Medicine.
LTGO is currently trading at $18.74, a 4.44% premium to Tananbaum's purchase price of $18.00. The stock is down 15.55% from its 52-week high of $22.19 but remains 7.02% above its 52-week low of $17.51.
Something here stands out, but not much.
| Filing → |
| ALMS | BUY | 2025-11-19 | $3.8M | — | Filing → |
| ALMS | BUY | 2025-05-06 | $202K | — | Filing → |
| ALMS | BUY | 2024-07-03 | $40.0M | — | Filing → |